OTC allergy spray cuts COVID-19 risk by 70%
Common allergy spray azelastine reduces COVID-19 infection risk by 70% in clinical trial.
Why it matters
- Provides an additional, accessible protective measure against COVID-19.
- Complements existing vaccines and protective measures.
- Potential for use in high-risk settings like crowded events and healthcare.
By the numbers
- 450 participants, average age 33.
- 70% reduction in COVID-19 infections (2.2% vs. 6.7%).
- Fewer symptomatic COVID cases (1.8% vs. 6.3%).
The big picture
- Azelastine is already available over-the-counter in some countries.
- Could be used as an additional layer of protection alongside vaccines.
- Potential for reducing respiratory infections in high-risk settings.
What they're saying
- Some users report sedative effects, which could limit frequent use.
- Suggestions for using the spray before entering crowded areas.
- Interest in the mechanism of action and potential for other prophylactic nasal sprays.
Caveats
- Modest sample size (450 participants).
- Mostly young, healthy, vaccinated participants.
- Conducted at a single German hospital.
What’s next
- Larger, multicenter trials needed to confirm results.
- Further research on effectiveness against other respiratory pathogens.